We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · May 05, 2022

Low-Dose Nivolumab With or Without Ipilimumab as Adjuvant Therapy After Resection of Melanoma Metastases

Cancers

 

Additional Info

Cancers
Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial
Cancers (Basel) 2022 Jan 28;14(3)682, JK Schwarze, S Garaud, YJL Jansen, G Awada, V Vandersleyen, J Tijtgat, A de Wind, P Kristanto, T Seremet, K Willard-Gallo, B Neyns

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading